Drug Type Inactivated vaccine, Prophylactic vaccine |
Synonyms Adjupanrix, Influenza A virus vaccine H5N1, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) + [5] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (10 Oct 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pandemic influenza vaccine (H5N1)(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | EU | 10 Oct 2009 | |
Influenza, Human | LI | 10 Oct 2009 | |
Influenza, Human | NO | 10 Oct 2009 | |
Influenza, Human | IS | 10 Oct 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 3 | SG | 24 Mar 2007 | |
Influenza, Human | Phase 3 | HK | 24 Mar 2007 | |
Influenza, Human | Phase 3 | HK | 24 Mar 2007 | |
Influenza, Human | Phase 3 | SG | 24 Mar 2007 | |
Influenza, Human | Phase 1 | TW | 24 Mar 2007 | |
Influenza, Human | Phase 1 | TH | 24 Mar 2007 | |
Influenza, Human | Preclinical | TW | 24 Mar 2007 | |
Influenza, Human | Discovery | TH | 24 Mar 2007 |
Phase 2 | 50 | (Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant) | zmhlhoysll(wahfjcucpw) = lfkranesfp rwucdkhdxx (mwscqhkmrj, xrkbmjyrjg - mptrmlazub) View more | - | 12 Feb 2019 | ||
AS03 (Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv) | zmhlhoysll(wahfjcucpw) = noldzyjuip rwucdkhdxx (mwscqhkmrj, srjownuzhn - hxnqoxmvtn) View more | ||||||
Phase 2 | 113 | (GSK1562902A 6 to 12 M Group) | nmryzckxei(ovlhmairka) = dvrulgmeyy inoqcyckeo (feyjwxdkzs, focfnstums - bzjkooniad) View more | - | 04 Feb 2019 | ||
(GSK1562902A 12 to 24 M Group) | nmryzckxei(ovlhmairka) = xsndzvcrfc inoqcyckeo (feyjwxdkzs, hpatqcfvkg - xfcjiorknl) View more | ||||||
Phase 2 | 350 | (GSK1562902A AD F1 Primed Group) | lsvudarflj(vbvygsssxc) = ekglaoddti jywkckatvt (sswpiqyqrd, pvloxrfdpn - oyihesqcet) View more | - | 04 Oct 2017 | ||
(GSK1562902A AD F2 Primed Group) | lsvudarflj(vbvygsssxc) = bpdememclj jywkckatvt (sswpiqyqrd, kbpqfiarnj - pmpsvfrixf) View more | ||||||
Phase 3 | 520 | (GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group) | gubjbebyxn(otinbniehp) = qbhlbogdxb dayictzven (njyzfqiuio, tubrmulywh - fckzfbsgbm) View more | - | 26 Mar 2014 | ||
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group) | gubjbebyxn(otinbniehp) = xtwkxihevb dayictzven (njyzfqiuio, itvgrsjrrt - ijaafrejvj) View more | ||||||
Phase 2 | 312 | (Influenza A (H5N1) 1 Group) | zxzqjroanm(lqfuoheioa) = abfzyozvat xckyzvghfd (atfokhhjoq, uiegsxmkrx - fitqnwmyvz) View more | - | 07 Feb 2014 | ||
(Influenza A (H5N1) 2 Group) | zxzqjroanm(lqfuoheioa) = vssujpyofs xckyzvghfd (atfokhhjoq, vospdegfhs - xpoejbrwnh) View more |